Since February life has changed for everyone. I back in sunny England, some days being warmer than the South of France! I have also been thrown into the world of
Avacta released its unaudited interim results for the six-month period ended 30 June 2020 on Monday. They detailed a period of significant advancement for the Group despite the restrictions placed upon it
Affimer-based research assay launched alongside performance data published by Bruker
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, will announce its unaudited interim results for the 6 months ended 30 June 2020 on Monday, 28 September
Avacta has announced that it will launch a high-performance Affimer research enzyme-linked immunosorbent assay (‘ELISA’) test in order to support global research efforts into the coronavirus that causes COVID-19.
Recognising that manufacturing capacity now represents the key challenge it faces in the global provision of its innovative, rapid, saliva-based SARS-CoV-2 antigen test that is being developed with Cytiva (formerly GE Healthcare
Manufacturing agreement with Abingdon Health for Avacta’s rapid COVID-19 saliva test
Avacta has announced the expansion of its existing multi-target collaboration and development agreement with LG Chem Life Sciences (‘LG Chem’), the life sciences division of the South Korean LG Group.
Avacta has announced an extension to its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. (KSX: 069620, ‘Daewoong’). AffyXell Therapeutics, the joint venture established in South Korea by the